Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2023 May 19;13:1218781. doi: 10.3389/fonc.2023.1218781

Corrigendum: The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway

Fuming Xie 1,2,3,4,, Yao Zheng 4,5,, Wen Fu 1,2,3,4, Bojing Chi 4,6, Xianxing Wang 4,5, Junfeng Zhang 4, Jianyou Gu 4, Jingyang Yin 1,2,3,4, Qiang Zhou 4,5, Shixiang Guo 4,5, Lei Cai 4, Jiali Yang 4,5,*, Songsong Liu 7,*, Huaizhi Wang 1,2,3,4,5,*
PMCID: PMC10237154  PMID: 37274238

Error in Figure/Table

In the published article, there was an error in Figures 3D, F as published. The incorrect images were included. The corrected Figures 3D, F and its caption appear below.

Figure 3.

Figure 3

METTL16 inhibits tumor growth in mice. (A) Nude mice were subcutaneously implanted with sh-NC or sh-METTL16 PC cells, and subcutaneous tumor nodules formed in the two groups of mice. (B) The weekly tumor volumes of the METTL16-knockdown and control groups are presented in the chart. (C) The mean tumor weights of the METTL16-knockdown and control groups 6 weeks after inoculation are presented. Two groups of tumor specimens were subjected to immunohistochemical detection of METTL16 (D, G), PCNA (E, H) and Ki67 (F, I). * means p<0.05; ** means p<0.01; *** means p<0.001.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES